Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock Has Average Price Target of $40.86

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $40.86.

A number of equities analysts have weighed in on LYEL shares. Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a research report on Friday, August 14th. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Friday, July 17th. Stifel Nicolaus assumed coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They set a “buy” rating and a $36.00 target price for the company. Finally, Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Saturday, September 26th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Opaleye Management Inc. grew its position in Lyell Immunopharma by 334.9% during the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after buying an additional 264,928 shares during the period. Squarepoint Ops LLC grew its holdings in Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after purchasing an additional 23,028 shares during the period. Velan Capital Investment Management LP increased its position in Lyell Immunopharma by 2.9% in the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock worth $1,475,000 after buying an additional 3,000 shares in the last quarter. venBio Partners LLC purchased a new stake in Lyell Immunopharma in the second quarter worth about $4,744,643. Finally, Bank of New York Mellon Corp bought a new position in shares of Lyell Immunopharma in the second quarter worth about $347,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Stock Down 5.1%

NASDAQ:LYEL opened at $8.61 on Friday. The stock has a market cap of $210.94 million, a price-to-earnings ratio of -0.67 and a beta of -0.03. The company’s 50 day moving average price is $12.80 and its 200-day moving average price is $15.68. Lyell Immunopharma has a 52 week low of $8.59 and a 52 week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.94) by $0.02. The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. As a group, sell-side analysts anticipate that Lyell Immunopharma will post -7.16 earnings per share for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for cancer, with an emphasis on solid tumors. The company seeks to address limitations of existing cell therapies, including T-cell exhaustion, limited persistence and reduced activity within the tumor microenvironment.

Lyell uses cell-engineering and genomic technologies to develop investigational chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies.